• About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard
Veterinary Cannabis SocietyVeterinary Cannabis Society
  • About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard

The nonpsychoactive cannabis constituent cannabidiolis an oral anti-arthritic therapeutic in murinecollagen-induced arthritis

Home The nonpsychoactive cannabis constituent cannabidiolis an oral anti-arthritic therapeutic in murinecollagen-induced arthritis

Curated Research Library

  • Back to Curated Research Library

The nonpsychoactive cannabis constituent cannabidiolis an oral anti-arthritic therapeutic in murinecollagen-induced arthritis

  • By: Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9561-6. doi: 10.1073/pnas.160105897. PMID: 10920191; PMCID: PMC16904.
  • Published On: 15 August, 2000
  • Publication: pubmed
  • Tags: general
  • Category: Osteoarthritis

The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund’s adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. CBD was administered after onset of clinical symptoms, and in both models of arthritis the treatment effectively blocked progression of arthritis. CBD was equally effective when administered i.p. or orally. The dose dependency showed a bell-shaped curve, with an optimal effect at 5 mg/kg per day i.p. or 25 mg/kg per day orally. Clinical improvement was associated with protection of the joints against severe damage. Ex vivo, draining lymph node cells from CBD-treated mice showed a diminished CII-specific proliferation and IFN-gamma production, as well as a decreased release of tumor necrosis factor by knee synovial cells. In vitro effects of CBD included a dose-dependent suppression of lymphocyte proliferation, both mitogen-stimulated and antigen-specific, and the blockade of the Zymosan-triggered reactive oxygen burst by peritoneal granulocytes. It also was found that CBD administration was capable of blocking the lipopolysaccharide-induced rise in serum tumor necrosis factor in C57/BL mice. Taken together, these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA.

Click Here to Access Article
  • Back to Curated Research Library
Search

Our Mission is to create lasting solutions that ensure the safe use of cannabis in pets through education, advocacy, and promoting product standards.

Our Vision is an educated and empowered global veterinary medical cannabis community.

  • About Us
  • Our Work
  • Get Involved
  • Contact Us
  • Donate

Email:
Click here to email us

Florida Mailing Address
7901 4th St. North, Suite 4404
St. Petersburg, FL 33702

Veterinary Cannabis Society is a nonprofit, 501(c)(3) organization in the United States. Tax ID #85-0986090

Veterinary Cannabis Society does not endorse any specific products.

© 2025 · Veterinary Cannabis Society

  • Terms of Use
  • Privacy Policy
  • State Notices
  • Contact